Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
@article{TLCR68883, author = {Xiaobo Yang and Chengpei Zhu and Haitao Zhao}, title = {Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration}, journal = {Translational Lung Cancer Research}, volume = {11}, number = {10}, year = {2022}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/68883} }